Author:
Snider Molly J. E.,Bheemidi Abhinav R.,Muste Justin C.,Valentim Carolina C. S.,Wu Shirley Z.,Bhatter Param,Singh Rishi P.
Abstract
Background and Objectives:
To pool available data on the change in best-corrected visual acuity (BCVA), central retinal thickness (CRT), and number of injections as reported by treat and extend (T&E) and pro re nata (PRN) regimens for retinal vein occlusion (RVO).
Materials and Methods:
After PubMed was queried, separate random effect models were fitted to the data extracted and the Wald test was used to compare the estimates of the two independent meta-analyses.
Results:
Fourteen T&E and 29 PRN studies were included in two independent meta-analyses. No significant difference was observed in BCVA (+14.74 [+11.52, +17.96] in T&E vs +15.90 [+14.24, + 17.56] in PRN,
P
= 0.530) or CRT improvements (−259.56 [−189.02, −330.09] in T&E vs −256.58 [−226.57, −286.48] in PRN,
P
= 0.939). More injections over 12 months were observed in T&E regimens (7.48 [6.32, 8.65] vs 5.13 [4.20, 6.06] in PRN,
P
= 0.002).
Conclusion:
Although more injections may be required, T&E achieves similar functional and anatomic benefits as compared to PRN regimens.
[
Ophthalmic Surg Lasers Imaging Retina
2023;54:244–250.]